Positive Quality Intervention: Zanubrutinib (Brukinsa®) Patient Selection and Management

Description: The purpose of this PQI is to identify differentiating characteristics which would indicate zanubrutinib as the preferred treatment option in Mantle Cell Lymphoma (MCL) and to discuss key counseling and monitoring criteria to improve patient outcomes.

Background: Zanubrutinib is a potent, highly specific, and irreversible inhibitor of Bruton’s tyrosine kinase (BTK). Zanubrutinib received FDA breakthrough therapy designation for the treatment of adult patients with relapsed/refractory MCL following at least one prior therapy on November 14, 2019, based on data from a phase I and a phase II trial.1-2 Eighty-six patients with relapsed/refractor MCL were treated with zanubrutinib 160 mg twice daily in the phase II study. After median follow up of 18.4 months, an objective response was seen in 72 (84%) patients with complete response achieved in 59 (68.6%). The most common Grade 3 or worse adverse events were neutropenia (19.8%) and lung infection/pneumonia (9.3%). Major bleeding events occurred in 3 patients, and atrial fibrillation was not seen. Zanubrutinib has also gained approval in chronic lymphocytic leukemia, marginal zone lymphoma, and Waldenström macroglobulinemia.3 Zanubrutinib has shown greater selectivity for BTK with fewer off-target receptor interactions compared to the currently approved agents in the class.4 Potential side effects seen with BTK inhibitors are likely related to off-target interaction with other receptors including epidermal growth factor receptor (EGFR) and interleukin-2-inducible T-cell kinase (ITK).1-2,5 A phase I/II trial evaluated zanubrutinib 160 mg twice daily or 320 mg once daily in 144 patients with various B-cell malignancies. Safety analysis in these patients showed a less than 2% incidence of both atrial fibrillation (Afib) and major hemorrhage which are potential grade 3/4 adverse effects seen with other BTK inhibitors.2

PQI Process:3 Upon receipt of an order for zanubrutinib:

- Ensure patient is appropriate candidate for zanubrutinib based on indication
  - Patient comorbidities may make zanubrutinib a safer option (ex. history of Afib, recent hemorrhage, hypertension, concomitant PPI or H2R antagonists)
- Dose of zanubrutinib: 160 mg by mouth twice daily or 320 mg once daily
- Reduce zanubrutinib dose accordingly if co-administered with:
  - Strong CYP3A inhibitor – 80 mg once daily
  - Moderate CYP3A inhibitor – 80 mg twice daily
  - Moderate or strong CPY3A inducer – avoid concomitant use
- Reduce dose to 80 mg twice daily in patients with severe hepatic impairment (Child-Pugh Class C)
- Consider prophylaxis for herpes simplex virus, Pneumocystis jirovecii pneumonia, and other infections according to standard of care in patients at increased risk for infections
  - ≥Grade 3 infections occurred in 24% of patients with pneumonia being the most common2
- Verify monitoring parameters:
  - CBC with differential, hepatic function
  - Signs/symptoms of Afib/flutter, bleeding, or infections including opportunistic infections
- See full prescribing information for dose modifications with Grade 3 or worse adverse effects
**Patient-Centered Activities:**
- Provide [Oral Chemotherapy Education (OCE)](OCE) sheet
- Counsel to administer orally, review once a day vs twice a day dosing
- Proper sign/symptom monitoring
- Evaluate if patients have missed any doses between cycles; consider reminders, calendars, pill box, etc
- Patient Assistance: [NCODA Financial Assistance Tool](NCODA)

**References:**
3. Brukinsa (zanubrutinib) [package insert].